Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interleukin‑1 beta signaling pathway encompasses all molecular events initiated by binding of interleukin‑1 beta—a pro-inflammatory cytokine—to its primary cell surface receptor IL‑1RI. This triggers recruitment of accessory proteins and intracellular adapters that activate downstream kinases and transcription factors such as NF-kB and MAPKs, leading to upregulation of genes involved in inflammation, immune cell activation, fever induction, and tissue remodeling. Dysregulation or overactivation contributes to various diseases including autoimmune disorders, chronic inflammation, neurodegeneration, and cancer[2][3][4].
Blocking cytokine-receptor interaction to inhibit downstream inflammatory responses
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-1 beta signaling pathway (IL-1β signaling pathway).